Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders
by
Altamura AC, Pioli R, Vitto M, Mannu P
Department of Psychiatry,
University of Milan,
Istituto Scienze Biomediche, Italy.
Int Clin Psychopharmacol 1999 Jul; 14(4):239-45

ABSTRACT

The study aimed to evaluate the clinical response to venlafaxine in social phobia in 12 patients who were non-responders to selective serotonin reuptake inhibitors, and to assess how the response could be influenced by the comorbidity in Axis II with avoidant personality disorder (APD). The duration of the study was of 15 weeks using open flexible doses regimen in individuals with or without concomitant APD. The venlafaxine dose ranged from 112.5 mg/day to 187.5 mg/day. Venlafaxine improves social phobia and/or APD symptomatology, as demonstrated by decreasing Liebowitz Social Anxiety Scale total scores (P < 0.05). In fact, venlafaxine significantly reduced the avoidant behaviour and specific sociophobic aspects, while notably improving the depression dimension and the basic anxiety symptoms. With regard to tolerability, the profile of venlafaxine was satisfactory with the main side-effects being nausea, headache and anxiety.

SSRIs
Anxiety
Serotonin
Buspirone
Alprazolam
Benzodiazepines
Venlafaxine for GAD
Venlafaxine compared
Anxiety and depression
Venlafaxine v fluoxetine
Venlafaxine pharmacology
Venlafaxine plus buspirone
Venlafaxine plus bupropion
Venlafaxine and major depression
Venlafaxine XR for anxiety disorders
Venlafaxine and headache prevention
Venlafaxine (Effexor) v clomipramine for OCD
Venlafaxine ER for generalized anxiety disorder (GAD)
February 2008: FDA licenses antidepressant desvenlafaxine (Pristiq)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family